Surveillance strategy | Imaging-detected local relapse | Imaging-detected regional relapse | Imaging-detected distant metastasis | Total imaging studies performed | Imaging studies per recurrencea | Pb |
---|---|---|---|---|---|---|
Stage I | ||||||
 cfEBV DNA-guided MRI + CT + BS | 102 | 20 | 87 | 19,703 | 94 |  |
 cfEBV DNA-guided PET/CT | 103 | 21 | 98 | 19,676 | 89 |  |
 Routine MRI + CT + BS | 112 | 23 | 78 | 97,493 | 457 | < .001 |
 Routine PET/CT | 119 | 24 | 99 | 97,519 | 405 | < .001 |
Stage II | ||||||
 cfEBV DNA-guided MRI + CT + BS | 199 | 306 | 354 | 21,265 | 25 |  |
 cfEBV DNA-guided PET/CT | 202 | 307 | 399 | 21,170 | 23 |  |
 Routine MRI + CT + BS | 216 | 316 | 309 | 101,670 | 121 | < .001 |
 Routine PET/CT | 228 | 319 | 410 | 101,595 | 106 | < .001 |
Stage III | ||||||
 cfEBV DNA-guided MRI + CT + BS | 344 | 339 | 596 | 25,010 | 20 |  |
 cfEBV DNA-guided PET/CT | 349 | 340 | 671 | 24,855 | 18 |  |
 Routine MRI + CT + BS | 368 | 349 | 538 | 118,328 | 94 | < .001 |
 Routine PET/CT | 389 | 350 | 672 | 118,204 | 84 | < .001 |
Stage IV | ||||||
 cfEBV DNA-guided MRI + CT + BS | 571 | 484 | 1166 | 25,893 | 12 |  |
 cfEBV DNA-guided PET/CT | 580 | 486 | 1324 | 25,598 | 11 |  |
 Routine MRI + CT + BS | 610 | 502 | 1101 | 117,829 | 53 | < .001 |
 Routine PET/CT | 640 | 508 | 1372 | 117,440 | 47 | < .001 |